RecruitingPhase 2NCT05512208
A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
Studying Mucinous adenocarcinoma of ovary
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Oklahoma
- Principal Investigator
- Christina Washington, MDOU Health Stephenson Cancer Center
- Intervention
- Avutometinib (VS-6766) + defactinib(drug)
- Enrollment
- 55 target
- Eligibility
- 18-99 years · FEMALE
- Timeline
- 2023 – 2029
Study locations (4)
- AdventHealth, Orlando, Florida, United States
- Louisiana State University Medical Center New Orleans, New Orleans, Louisiana, United States
- University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, United States
- Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
Collaborators
Verastem, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05512208 on ClinicalTrials.gov